Kayser, Sabine and Schlenk, Richard F. and Lebon, Delphine and Carre, Martin and Goetze, Katharina S. and Stoelzel, Friedrich and Berceanu, Ana and Schaefer-Eckart, Kerstin and Peterlin, Pierre and Hicheri, Yosr and Rahme, Ramy and Raffoux, Emmanuel and Chermat, Fatiha and Krause, Stefan W. and Aulitzky, Walter E. and Rigaudeau, Sophie and Noppeney, Richard and Berthon, Celine and Goerner, Martin and Jost, Edgar and Carassou, Philippe and Keller, Ulrich and Orvain, Corentin and Braun, Thorsten and Saillard, Colombe and Arar, Ali and Kunzmann, Volker and Wemeau, Mathieu and de Wit, Maike and Niemann, Dirk and Bonmati, Caroline and Schwaenen, Carsten and Abraham, Julie and Aljijakli, Ahmad and Haiat, Stephanie and Kraemer, Alwin and Reichle, Albrecht and Gnadler, Martina and Willekens, Christophe and Spiekermann, Karsten and Hiddemann, Wolfgang and Mueller-Tidow, Carsten and Thiede, Christian and Roellig, Christoph and Serve, Hubert and Bornhaeuser, Martin and Baldus, Claudia D. and Lengfelder, Eva and Fenaux, Pierre and Platzbecker, Uwe and Ades, Lionel (2021) Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative. HAEMATOLOGICA, 106 (12). pp. 3100-3106. ISSN 0390-6078,
Full text not available from this repository. (Request a copy)Abstract
The aim of this study was to characterize a large series of 154 patients with acute promyelocytic leukemia (median age, 53 years; range, 18-90 years) and evaluate real-life outcome after up-front treatment with arsenic trioxide and all-trans retinoic acid. All patients were included in the prospective NAPOLEON registry (NCT02192619) between 2013 and 2019. The acute promyelocytic leukemia was de novo in 91% (n=140) and therapy-related in 9% (n=14); 13% (n=20) of the patients were older than 70 years. At diagnosis bleeding/hemorrhage was present in 38% and thrombosis in 3%. Complete remission was achieved in 152 patients (99%), whereas two patients (1%) experienced induction death within 18 days after starting therapy. With a median follow-up of 1.99 years (95% confidence interval: 1.61-2.30 years) 1-year and 2-year overall survival rates were 97% (95% confidence interval: 94-100%) and 95% (95% confidence interval: 91-99%), respectively. Age above 70 years was associated with a significantly shorter overall survival (P<0.001) compared to that of younger patients. So far no relapses have been observed. Six patients (4%) died in complete remission at a median of 0.95 years after diagnosis (range, 0.18-2.38 years). Our data confirm the efficiency and durability of arsenic trioxide and all-trans retinoic acid therapy in the primary management of adults with low-/intermediate-risk acute promyelocytic leukemia in the real-life setting, irrespective of age.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | TRANS-RETINOIC ACID; ADDITIONAL CHROMOSOME-ABNORMALITIES; ACUTE MYELOID-LEUKEMIA; FRONT-LINE THERAPY; LONG-TERM EFFICACY; EARLY DEATH; FLT3 GENE; TANDEM DUPLICATION; PROGNOSTIC-FACTORS; FOLLOW-UP; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 04 Oct 2022 08:35 |
| Last Modified: | 04 Oct 2022 08:35 |
| URI: | https://pred.uni-regensburg.de/id/eprint/48204 |
Actions (login required)
 |
View Item |
